A 49-year-old female patient with recurrent cervical cancer was treated with injectable paclitaxel (albumin-bound) (400 mg, ivd, d1) + injectable cisplatin 100 mg, intraperitoneal instillation, d1+ candonilimab injection (375 mg, ivd, d7). During the 2nd cycle of treatment, when the intravenous infusion of candonilimab was about 8 minutes, the patient suddenly had symptoms such as flushing, shortness of breath, cardiac discomfort, blurred consciousness with profuse sweating, etc. The candonilimab was immediately suspended, and after resuscitation, the patient's vital signs stabilised, and the treatment of the primary disease with candonilimab was terminated.According to the principle of correlation evaluation in Adverse Drug Reaction Reporting and Monitoring Workbook, the correlation between anaphylaxis and candonilimab was evaluated to be "very likely", and the common types of adverse reactions to candonilimab, the mechanism of anaphylaxis and pretreatment measures were also reviewed, with a view to providing referable opinions on the whole course of management of candonilimab and promoting the rational use of the drug in clinical safety.

1.龙行涛, 周琦, 林仲秋. 子宫颈癌免疫检查点抑制剂临床应用指南（2024年版）[J]. 中国实用妇科与产科杂志, 2024, 40(7): 712-719. [Long XT, Zhou Q, Lin ZQ. Guideline for clinical application of immune checkpoint inhibitors for cervical cancer (2024 edition)[J]. Chinese Journal of Practical Gynecology and Obstetrics, 2024, 40(7): 712-719.] DOI: 10.19538/j.fk2024070111.

2.Baumeister SH, Freeman GJ, Dranoff G, et al. Coinhibitory pathways in immunotherapy for cancer[J]. Annu Rev Immunol, 2016, 34: 539-573. DOI: 10.1146/annurev-immunol-032414 -112049.

3.卓青婵, 朱敏莹, 左瑜芳, 等. 国产PD-1抑制剂在妇科肿瘤中的研究现状[J]. 临床医学研究与实践, 2024, 9(8): 184-190. [Zhuo QC, Zhu MY, Zuo YF, et al. Research status of domestic PD-1 inhibitors in gynecological tumors[J]. Clinical Research and Practice, 2024, 9(8): 184-190.] DOI: 10.19347/j.cnki.2096-1413. 202408045.

4.国家药品不良反应监测中心. 药品不良反应报告和监测工作手册[S]. 2012: 49-51.

5.Cardona V, Ansotegui IJ, Ebisawa M, et al. World allergy organization anaphylaxis guidance 2020[J]. World Allergy Organ J, 2020, 13(10): 100472. DOI: 10.1016/j.waojou.2020.100472.

6.美国卫生及公共服务部. 常见不良事件评价标准（CTCAE）5.0版[EB/OL]. (2017-11-27) [2021-06-20]. https://guide.medlive.cn/guidelinesub/5061.

7.李金兰, 潘勇, 曾媚姿, 等. 卡度尼利单抗不良反应临床特点分析[J]. 中国新药杂志, 2024, 33(6): 619-624. [Li JL, Pan Y, Zeng MZ, et al. Analysis of the clinical characteristics of adverse reactions associated with cadonilimab[J]. Chinese Journal of New Drugs, 2024, 33(6): 619-624.] DOI: 10.3969/j.issn.1003-3734. 2024.06.015.

8.涂云霞, 华金仁, 刘荣芳, 等. 卡度尼利单抗治疗复发性/晚期宫颈癌的有效性和安全性[J]. 现代妇产科进展, 2024, 33(2): 133-136. [Tu YX, Hua JR, Liu RF, et al. Efficacy and safety of cadonilimab in the treatment of recurrent/advanced cervical cancer[J]. Progress in Obstetrics and Gynecology, 2024, 33(2): 133-136.] DOI: 10.13283/j.cnki.xdfckjz.2024.02.007.

9.付瑛, 张苗, 王华庆. 卡度尼利单抗治疗原发中枢神经系统弥漫大B细胞淋巴瘤致剥脱性皮炎1例[J]. 中国肿瘤临床与康复, 2023, 30(9): 583-585. [Fu Y, Zhang M, Wang HQ. Exfoliative dermatitis in a patient with primary central nervous system diffuse large B-cell lymphoma after candonilimab therapy[J]. Journal of Clinical Oncology and Rehabilitation, 2023, 30(9): 583-585.] DOI: 10.13455/j.cnki.cjcor.113494-20231127-0182.

10.徐倩, 徐婷. 卡度尼利单抗注射液治疗晚期胃癌致垂体危象1例[J]. 药物流行病学杂志, 2024, 33(1): 116-120.[Xu Q, Xu T. A case of pituitary crisis caused by cadonilimab treatment of advanced gastric cancer[J]. Chinese Journal of Pharmacoepidemiology, 2024, 33(1): 116-120.] DOI: 10.12173/j.issn.1005-0698.202312065.

11.陈杰, 张斌, 赵俊, 等. 托珠单抗注射液致过敏性休克1例分析[J]. 中国药物警戒, 2024, 21(3): 349-351. [Chen J, Zhang B, Zhao J, et al. One case of allergic shock caused by tocilizumab injection[J]. Chinese Journal of Pharmacovigilance, 2024, 21(3): 349-351.] DOI: 10.19803/j.1672-8629.20230594.

12.Chung CH. Managing premedications and the risk for reactions to infusional monoclonal antibody therapy[J]. Oncologist, 2008, 13(6): 725-732. DOI: 10.1634/theoncologist.2008-0012.

13.Lenz HJ. Management and preparedness for infusion and hypersensitivity reactions[J]. Oncologist, 2007, 12(5): 601-609. DOI: 10.1634/theoncologist.12-5-601.

14.Tsujimura Y, Obata K, Mukai K, et al. Basophils play a pivotal role in immunoglobulin-G-mediated but Not immunoglobulin-E-mediated systemic anaphylaxis[J]. Immunity, 2008, 28(4): 581-589. DOI: 10.1016/j.immuni.2008.02.008.

15.倪春艳, 张蕾. 替雷利珠单抗致过敏性休克1例[J]. 医药导报, 2023, 42(10): 1576-1577. [Ni CY, Zhang L. One case of anaphylaxis caused by tirilizumab injection[J]. Herald of Medicine, 2023, 42(10): 1576-1577.] DOI: 10.3870/j.issn.1004-0781.2023. 10.028.

16.黄淑贞, 陈雄剑. 帕博利珠单抗注射液致过敏性休克1例[J]. 药物流行病学杂志, 2024, 33(10): 1196-1200. [Huang SZ, Chen XJ. One case of anaphylaxis caused by pembrolizumab injection[J]. Chinese Journal of Pharmacoepidemiology, 2024, 33(10): 1196-1200.] DOI: 10.12173/j.issn.1005-0698.202408052.